Mergers & Acquisitions - Akorn


Current filters:


Popular Filters

Akorn to acquire VersaPharm for $440 million

Akorn to acquire VersaPharm for $440 million


Following swiftly on its completion of the acquisition of Hi-Tech Pharmacal (Nasdaq: HITK) for $640 million…

AkornDermatologicalsGenericsMergers & AcquisitionsVersaPharm

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal


In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

Akorn gains rights to Betimol from Santen


US niche generic firm Akorn has acquired the New Drug Application and all rights to Betimol (timolol…

AkornBetimolMergers & AcquisitionsOphthalmicsPharmaceuticalSanten Pharmaceuticals

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs


USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

Akorn buy of Hi-Tech Pharmacal delayed by FTC request


In a filing with the US Stock Exchange Commission, USA-based niche generics firm Akorn announced that…

AkornGenericsHi-Tech PharmacalMergers & Acquisitions

Akorn buys rival generic drugmaker for $640 million


USA-based generics drugmaker Akorn (Nasdaq: AKRX) has bought rival generic drugmaker Hi-Tech Pharmacal…

AkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth America

Lundbeck divests three branded injectables to Akorn


Danish CNS drug specialist Lundbeck (LUND: DC) says it has entered into an agreement with USA-based niche…

AkornCogentinDiurilGenericsLundbeckMergers & AcquisitionsNembutalNeurologicalNorth AmericaPharmaceutical

Akorn buys minority stake in ophthalmic firm Aciex; posts strong 2nd-qrtr 2011 earnings


US specialty pharma company Akorn (Nasdaq: AKRX), has entered into an agreement to acquire an unspecified…

Aciex TherapeuticsAkornFinancialGenericsMergers & AcquisitionsOphthalmicsPharmaceutical

Back to top